×

Myriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium

New Data on the myChoice® HRD and myRisk™ Hereditary Cancer Tests Will be Highlighted

SALT LAKE CITY, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it will present eight posters at the 2015 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 8 to 12, 2015 in San Antonio, Texas.

"Myriad is committed to bringing transformative molecular diagnostics to people with cancer. Our data at SABCS showcase our expanding portfolio of companion diagnostics and their potential to help personalize treatments for people with breast cancer," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "We're also excited about several new studies that highlight the ability of our myRisk Hereditary Cancer test to identify patients at risk for hereditary cancers."

A list of the Myriad presentations at SABCS is below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #SABCS15.

myChoice HRD Poster Presentations

  • Title: The role of germline BRCA status and Homologous Recombination Deficiency and response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy.
    Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster P3-07-29.
  • Title: Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer.
    Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster P3-07-13.
  • Title: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC); A pooled analysis.
    Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster P3-07-12.

myRisk Hereditary Cancer Poster Presentations

  • Title: Predisposing germline mutations in an unselected academic breast cancer (BC) cohort.
    Date: Wednesday, Dec. 9, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster P1-08-07.
  • Title: The patient experience in a prospective trial of multiple-gene panel testing for cancer risk.
    Date: Thursday, Dec. 10, 2015: 7:30 to 9:00 a.m. CT.
    Location: Poster P2-09-07.
  • Title: Interim analysis of multiplex gene panel testing for inherited susceptibility to breast cancer.
    Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster Discussion PD7-01.
  • Title: Multiplex Identification of genetic etiologies among women with bilateral breast cancer using a 25-gene hereditary cancer panel.
    Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster Discussion PD7-02.
  • Title: Characterization of Li-Fraumeni syndrome diagnosed using a 25-gene hereditary cancer panel.
    Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
    Location: Poster Discussion PD7-03.

For more information about these presentations, please visit the SABCS website at https://www.sabcs.org/.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related the Company's commitment to bringing transformative molecular diagnostics to people with cancer; our expanding portfolio of companion diagnostics and their potential to help personalize treatments for people with breast cancer; the ability of our myRisk Hereditary Cancer test to identify patients at risk for hereditary cancers; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact: Ron Rogers (908) 285-0248 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com

Source:Myriad Genetics, Inc.